SARAH COOLING: Open Payments
NPI 1457525453 · LAKE CHARLES, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,227 in 143 payments from 15 companies in 2025. Trend: 2023 $2,088 · 2024 $1,934 · 2025 $2,227
Food & beverage: $2,227
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 22 | $396 |
| Otsuka America Pharmaceutical, Inc. | 24 | $294 |
| ABBVIE INC. | 25 | $290 |
| Neurocrine BioSciences, Inc. | 16 | $280 |
| Teva Pharmaceuticals USA, Inc. | 13 | $223 |
| Janssen Pharmaceuticals, Inc | 8 | $162 |
| Alkermes, Inc. | 11 | $161 |
| E.R. Squibb & Sons, L.L.C. | 5 | $98 |
| Supernus Pharmaceuticals, Inc. | 3 | $64 |
| Corium, LLC | 5 | $60 |
Products named: CAPLYTA, VRAYLAR, INGREZZA, REXULTI, ARISTADA, INVEGA SUSTENNA, AUSTEDO XR, UZEDY.
Industry payments across LA — which companies pay providers there.
